Explore our content from the 2025 ASCO Annual Meeting ++++ ++++

Explore our content from the 2025 ASCO Annual Meeting ARTICLES Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial Free with registration until Jun 11, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco25&_hsenc=p2ANqtz-9GmyGkDk3fOLhBu8cWB093k99nP8X_PXUvMRUwLy1rDwhtysxe1m-Y_BKxBxC2gOA0uUAaDb92Y1pbh9vRbhYZldj50g&_hsmi=364558193&utm_content=364558193&utm_source=hs_email Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study Free with registration until Jun 11, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00986-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco25&_hsenc=p2ANqtz-9o4B2aX15yJaPlfjgmSh7qjyDk9Sxm4EG00wgGguQmk7xEabd9fWMLdkZu4619JqMXDLGaAg9R99hdSx6bB3uR4lmS5w&_hsmi=364558193&utm_content=364558193&utm_source=hs_email Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial Free with registration until Jun 11, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01011-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco25&_hsenc=p2ANqtz-_IGNODiMpP2Mr9kSwyEKquGpMdfnsVSQNOQItVVc_opwRHqzQ4k4y7mre3nRmJq_dHeaGJHiydI20KL9p47FEvpbEXFg&_hsmi=364558193&utm_content=364558193&utm_source=hs_email Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial Free with registration until Jun 11, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco25&_hsenc=p2ANqtz-8Akp-2OiAT-aVrluxWgX2TnhJhBaIcpLosvQ5BcfFpQ7r4TqELPSQK3g6TFQb9pOsX7I9KDWz0sOnEJYhRm65wybWEAg&_hsmi=364558193&utm_content=364558193&utm_source=hs_email Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study Free with registration until Jun 11, 2025 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco25&_hsenc=p2ANqtz-9NzWkFkeNaD7aZSGgIQtajoFLFDjmoXv5K0O6qs653qCZhrWzsc9zUk_cl9QORg6dTQRsB9rWw5LaSaJgJEEe8yvS6dg&_hsmi=364558193&utm_content=364558193&utm_source=hs_email External validation of a digital pathology-based model derived from multimodal artificial intelligence in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol Open Access https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00067-6/fulltext?dgcid=hubspot_email_conferencealerts_asco25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8gM56hd-9RSyhnmpdgrLZRQC1yXB_c67C3jjpnQkv1pwUBswFpqOQqivatf1zpgPLigdrdcksA7rfqM46fWwygErV0qQ&_hsmi=364558193&utm_content=364558193&utm_source=hs_email Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study Open Access https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00020-3/fulltext?dgcid=hubspot_email_conferencealerts_asco25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_jZhAdWYo2Uj3cHcPwjJ2ys_3Keh0yInuldIhx6i2PjBYVRsrj_A8FQAFoOQivejuV4rWr-KW0CgpbrTSJJooSf-fnXg&_hsmi=364558193&utm_content=364558193&utm_source=hs_email COMMENTS Zanidatamab, a bispecific monoclonal antibody for HER2-positive gastro-oesophageal adenocarcinoma patients: a new hope? Free with registration until Jun 11, 2025 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00301-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco25&_hsenc=p2ANqtz-8txsm1w54eCbtlWMeY6pPXCmQkfv4hu3IdgltNXhLiLNzVy3uUOcZ8AVibVLKudaYJAzBC0O9jlF275zFZT7pzgyfeGw&_hsmi=364558193&utm_content=364558193&utm_source=hs_email